IVD in Cardiology and Neurology - Global Stategic Business Report

The global market for IVD in Cardiology and Neurology was estimated at US$17.3 Billion in 2024 and is projected to reach US$27.8 Billion by 2030, growing at a CAGR of 8.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the IVD in Cardiology and Neurology market.

IVD in Cardiology and Neurology Market - Key Trends & Drivers Summarized

In-vitro diagnostics (IVD) in cardiology and neurology is rapidly evolving, enabling early disease detection, risk assessment, and personalized treatment strategies. As cardiovascular and neurological disorders continue to be leading causes of mortality and disability worldwide, IVD technologies are playing a crucial role in improving patient outcomes. Advances in biomarker-based testing, molecular diagnostics, point-of-care (POC) testing, and digital health integration are driving innovation in this sector.

With the rising prevalence of heart disease, stroke, neurodegenerative disorders, and cognitive impairments, healthcare providers and researchers are increasingly relying on IVD solutions for accurate diagnosis, disease monitoring, and therapy optimization. The demand for high-sensitivity cardiac and neurological biomarkers, AI-driven diagnostics, and rapid testing solutions is fueling market growth and transforming clinical decision-making.

How Are Technological Advancements Enhancing IVD in Cardiology?

The field of cardiac in-vitro diagnostics has witnessed groundbreaking advancements, particularly in high-sensitivity assays, point-of-care cardiac biomarker testing, and molecular diagnostics. One of the most significant innovations is the development of high-sensitivity cardiac troponin (hs-cTn) tests, which enable the early detection of myocardial infarction (MI) and acute coronary syndrome (ACS). These ultrasensitive assays detect minute changes in cardiac troponin levels, allowing for earlier intervention, improved risk stratification, and reduced hospital admissions.

Another major breakthrough is the integration of multi-biomarker panels for cardiovascular disease risk assessment. Traditionally, lipid profiles (LDL, HDL, total cholesterol, and triglycerides) were the standard for evaluating cardiovascular health. However, modern IVD solutions now incorporate additional biomarkers such as high-sensitivity C-reactive protein (hs-CRP), natriuretic peptides (BNP/NT-proBNP), and myeloperoxidase (MPO) to provide comprehensive cardiovascular risk insights. These advanced biomarker assays are enabling personalized preventive strategies and early-stage cardiovascular disease (CVD) intervention.

The expansion of point-of-care (POC) testing for cardiac markers is another critical trend. Portable, rapid, and handheld POC analyzers now allow for real-time troponin, D-dimer, and BNP testing in emergency rooms, ambulances, and primary care settings. This has significantly improved early triage decisions, reduced turnaround times, and enhanced pre-hospital cardiac event management. Additionally, the rise of wearable biosensors and remote cardiac monitoring devices is enabling continuous cardiac health tracking, leading to proactive interventions and reduced hospitalizations for heart failure and arrhythmias.

Furthermore, molecular and genetic testing for inherited cardiovascular conditions is transforming disease prevention and management. Genetic screening for conditions such as familial hypercholesterolemia (FH), hypertrophic cardiomyopathy (HCM), and long QT syndrome (LQTS) is becoming more accessible, allowing early identification of at-risk individuals and targeted lifestyle or pharmacological interventions. The integration of AI-driven ECG interpretation and digital pathology is also advancing automated CVD diagnosis and prognosis prediction.

What Market Trends Are Driving IVD in Neurology?

The field of neurological diagnostics is undergoing rapid transformation, fueled by the increasing burden of neurodegenerative diseases, stroke, and cognitive disorders. One of the most significant trends is the development of blood-based biomarkers for Alzheimer’s disease (AD) and Parkinson’s disease (PD). Traditionally, the diagnosis of Alzheimer’s relied on cerebrospinal fluid (CSF) analysis or PET imaging, both of which are invasive and expensive. However, recent advancements in plasma-based assays for beta-amyloid (Aβ42/Aβ40 ratio), tau proteins (pTau-181, pTau-217), and neurofilament light chain (NfL) have enabled non-invasive and scalable screening for Alzheimer’s and other neurodegenerative diseases.

Another major trend is the expansion of molecular diagnostics in neurology, particularly in genetic testing for neurodevelopmental disorders, epilepsy, and neuromuscular conditions. Advances in next-generation sequencing (NGS) and CRISPR-based diagnostics are enabling early detection of genetic mutations linked to conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and hereditary ataxias. These precision diagnostic tools are facilitating personalized treatment selection, early interventions, and targeted gene therapies.

The rise of IVD solutions for stroke diagnosis and management is also driving market growth. Traditionally, stroke diagnosis relied on neuroimaging (CT, MRI); however, the introduction of stroke biomarker panels, including glial fibrillary acidic protein (GFAP), S100B, and D-dimer, is enhancing early stroke detection and differentiation between ischemic and hemorrhagic strokes. POC blood-based stroke tests are emerging as a game-changer for pre-hospital stroke assessment, allowing for rapid intervention and better patient outcomes.

Additionally, the growing integration of AI-driven neurodiagnostics, digital biomarkers, and remote monitoring is transforming neurological disease detection and progression tracking. AI-powered analysis of EEG, MRI, and speech patterns is improving the diagnosis of epilepsy, dementia, and movement disorders, while wearable neurotechnology is enabling real-time neuromonitoring for Parkinson’s, MS, and post-stroke rehabilitation.

What Is Driving the Growth of IVD in Cardiology and Neurology?

The IVD market in cardiology and neurology is expanding due to several key growth drivers, including the rising prevalence of cardiovascular and neurodegenerative diseases, advancements in biomarker discovery, and the growing demand for non-invasive diagnostics. One of the most significant growth drivers is the global burden of CVD and stroke, which remain the leading causes of death worldwide. As healthcare systems focus on early detection, prevention, and personalized treatment approaches, the demand for high-sensitivity cardiac biomarkers and rapid stroke diagnostics is accelerating.

Another critical driver is the aging population, which is contributing to the increased incidence of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. With early-stage detection and intervention becoming a priority, IVD solutions based on blood-based biomarkers, genetic screening, and AI-driven neuroimaging analysis are gaining traction.

The increasing adoption of point-of-care (POC) testing and decentralized diagnostics is also fueling market growth. The shift from hospital-based laboratory testing to portable, rapid diagnostic solutions is enabling quicker decision-making, improved patient triage, and better management of acute cardiac and neurological conditions. As emergency medicine, primary care, and home-based diagnostics expand, IVD manufacturers are investing in compact, user-friendly, and highly sensitive POC testing platforms.

Regulatory and reimbursement support for IVD-driven precision medicine is another major factor influencing market growth. Governments and healthcare agencies are promoting biomarker-driven treatment strategies, genetic testing for hereditary conditions, and AI-integrated diagnostics to optimize patient outcomes and reduce healthcare costs. Additionally, the rising investments in digital health technologies and remote patient monitoring are driving innovation in AI-powered cardiac and neurological diagnostics.

Report Scope

The report analyzes the IVD in Cardiology and Neurology market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Product Type (Instruments, Reagents & Consumables, Software & Services); Technology (Immunoassays, Molecular Diagnostics, Hematology, Others); End-Use (Hospitals, Clinical Laboratories, Others)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Instruments segment, which is expected to reach US$17.0 Billion by 2030 with a CAGR of a 9.8%. The Reagents & Consumables segment is also set to grow at 5.8% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $4.7 Billion in 2024, and China, forecasted to grow at an impressive 13.1% CAGR to reach $6.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global IVD in Cardiology and Neurology Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global IVD in Cardiology and Neurology Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global IVD in Cardiology and Neurology Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, Agilent Technologies, AliveCor, Becton, Dickinson and Company (BD), bioMérieux S.A. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 42 Featured):

• Abbott Laboratories
• Agilent Technologies
• AliveCor
• Becton, Dickinson and Company (BD)
• bioMérieux S.A.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• Hologic Inc.
• LivaNova
• Medtronic
• Mindray Medical International Limited
• Ortho Clinical Diagnostics
• PerkinElmer Inc.
• QIAGEN N.V.
• Roche Diagnostics
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry